EPR Properties (EPR) upgraded to Strong Buy: 7.3% yield, AFFO growth, and diversification away from theaters. Read here for a ...
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results